Agouron's Good News for Biotech
Executive Summary
Using its red-hot shares to buy assets, Warner-Lambert is acquiring Agouron, a company with higher growth but the same P/E multiple--and thus bringing with it no dilution. Other major drug companies, enjoying similarly high valued shares largely on account of their size, not their pipelines, should consider the same cost-effective strategy.